查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1584122

癌症支持治療藥物市場，按藥物類型、治療領域、分佈、最終用戶、國家和地區 - 2024-2032年產業分析、市場規模、市場佔有率和預測

Cancer Supportive Care Drugs Market, By Drug Type, By Therapeutic Area, By Distribution, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 301 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年癌症支持治療藥物市場規模為2,141,032萬美元，2024年至2032年年複合成長率為2.31%。

癌症支持治療藥物市場-市場動態

癌症發生率上升加速癌症支持治療藥物市場的成長

隨著越來越多的患者尋求治療方法來控制與治療相關的副作用，癌症發病率的上升大幅推動了癌症支持治療藥物市場的成長。據世界衛生組織（WHO）表示，癌症目前是全球第二大死亡原因，2020年將有近1000萬人死亡。癌症治療的患者的生活品質。例如，美國臨床腫瘤學會（ASCO）強調控制癌症患者中常見的噁心、疼痛和疲勞等症狀的重要性。此外，國家癌症研究所等組織倡導研究新型支持性護理藥物，進一步擴大了對有效治療的需求。隨著醫療保健提供者擴大對全面癌症護理的關注，支持療法市場預計將蓬勃發展，反映出在這一充滿挑戰的健康環境中改善患者治療結果的迫切需求。

癌症支持治療藥物市場 - 關鍵見解

根據研究分析師分享的分析，預計全球市場在預測期內（2024-2032年）每年將以 2.31%左右的年複合成長率成長

根據藥物類型細分，預計止吐藥將在2023年顯示最大的市場佔有率

根據治療區域細分，化療引起的噁心和嘔吐是2023年的主要類型

根據分佈細分，醫院藥局是2023年的主導類型

依地區分類，北美是2023年的主要收入來源

癌症支持治療藥物市場-細分分析：

全球癌症支持治療藥物市場根據藥物類型、治療領域、分佈、最終用戶和地區進行細分。

根據藥物類型，市場分為四類：紅血球生成促效劑、粒細胞集落刺激因子（G-CSF）、止吐劑和雙磷酸鹽。由於止吐劑在控制化療引起的噁心和嘔吐方面發揮重要作用，預計將佔據最大的市場佔有率。紅血球生成促效劑緊跟在後，因為它們有助於對抗癌症患者的貧血。粒細胞集落刺激因子（G-CSF）也很重要，支持化療後嗜中性球的恢復。雙磷酸鹽雖然對骨骼健康很重要，但與其他藥物類型相比，其市場佔有率相對較低。

根據治療領域，市場分為三類：化療引起的噁心和嘔吐、化療引起的貧血和嗜中性白血球減少症。化療引起的噁心和嘔吐是主要的治療領域，主要是因為這些副作用在接受治療的癌症患者中很常見。其次，化療引起的貧血位居第二，因為許多患者因治療而出現紅血球數低的情況。中性粒細胞減少症雖然也很重要，但與其他治療領域相比，其市場佔有率較小。

癌症支持治療藥物市場 - 地理洞察

癌症支持治療藥物市場的地理格局以北美地區的顯著成長為特徵，特別是在美國，癌症發病率高和先進的醫療基礎設施推動了需求。據美國癌症協會表示，估計2024年美國將新增約 190萬癌症病例，導致支持性護理藥物的使用增加。歐洲緊隨其後，德國和法國等國家投資於目的是改善癌症護理的創新治療方案和研究計劃。此外，在中國和印度等國家醫療保健支出不斷增加以及人們對癌症治療選擇的認知不斷提高的推動下，亞太地區成為市場擴張的一個值得注意的地區。世界衛生組織強調需要加強發展中地區的癌症護理，進一步推動支持性護理解決方案的成長。因此，公司致力於區域合作夥伴關係和量身定做的行銷策略，以滿足這些不同市場的特定需求。

癌症支持治療藥物市場-競爭格局：

癌症支持治療藥物市場的競爭格局以幾個關鍵參與者的存在為標誌，這些參與者積極致力於開發創新療法，以滿足日益成長的支持治療需求。Amgen、Roche和Merck等領先公司正致力於研究和開發，以增強其產品供應，特別是在止吐和粒細胞集落刺激因子（G-CSF）領域。例如，Amgen的Neulasta（pegfilgrastim）一直是 G-CSF 領域的領導者，有助於降低化療患者的感染風險。合作和夥伴關係也很常見，例如百時美施貴寶與各種醫療機構結盟以推進支持性護理的研究。此外，最近的收購，例如Pfizer收購 Array BioPharma，增強了公司在癌症治療領域的投資組合，包括支持性護理藥物。隨著公司不斷創新並擴大業務範圍，該市場的競爭仍然激烈，推動了癌症治療領域的進步，改善了患者的治療效果。

最新進展：

2023年 1月，Helsinn Healthcare SA 和 Immedica Pharma AB 簽署了一項獨家長期協議，在歐洲主要市場商業化兩種癌症支持護理產品 Akynzeo 和 Aloxi，目的是預防化療引起的噁心和嘔吐。

2024年 8月，FDA 批准了新一代酪胺酸激酶抑制劑 Augtyro（repotrectinib），用於治療 NTRK 陽性局部晚期或轉移性實體瘤患者，增強了癌症支持治療和標靶治療的選擇。

目錄

第1章 癌症支持治療藥物市場概述

  • 研究範圍
  • 市場預估年份

第2章 執行摘要

  • 市場摘錄
    • 依藥物類型分類的癌症支持治療藥物市場摘錄
    • 依治療領域分類的癌症支持治療藥物市場摘錄
    • 依分佈分類的癌症支持治療藥物市場摘錄
    • 依最終用戶的癌症支持治療藥物市場摘錄
    • 依國家/地區分類的癌症支持治療藥物市場摘錄
    • 依地區分類的癌症支持治療藥物市場摘錄
  • 競爭洞察

第3章 癌症支持治療藥物主要市場趨勢

  • 癌症支持治療藥物市場促進因素
    • 市場促進因素的影響分析
  • 癌症支持治療藥物市場限制
    • 市場限制影響分析
  • 癌症支持治療藥物市場機會
  • 癌症支持治療藥物市場未來趨勢

第4章 癌症支持治療藥物產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章 癌症支持治療藥物市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章 癌症支持治療藥物市場格局

  • 2023年癌症支持治療藥物市場佔有率分析
  • 依主要製造商分類的細分資料
    • 既有參與者分析
    • 新興參與者分析

第7章 癌症支持治療藥物市場 - 依藥物類型

  • 概述
    • 依藥物類型分類的細分市場佔有率分析
    • 紅血球生成促效劑
    • 粒細胞集落刺激因子（G-CSF）
    • 止吐藥
    • 雙磷酸鹽

第8章 癌症支持治療藥物市場 - 依治療領域

  • 概述
    • 依治療領域分類的細分市場佔有率分析
    • 化療引起的噁心和嘔吐
    • 化療引起的貧血
    • 嗜中性白血球減少症

第9章 癌症支持治療藥物市場 - 依分佈

  • 概述
    • 依分佈分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第10章 癌症支持治療藥物市場 - 依最終用戶

  • 概述
    • 依最終用戶分類的細分市場佔有率分析
    • 兒科患者
    • 成人患者
    • 老年患者

第11章 癌症支持治療藥物市場 - 依地理位置

  • 介紹
    • 依地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美癌症支持治療藥物主要製造商
    • 北美市場規模和預測（依國家）
    • 北美市場規模和預測（依藥物類型）
    • 北美市場規模與預測（依治療領域）
    • 北美市場規模和預測（依分佈）
    • 北美市場規模和預測（依最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲癌症支持治療藥物主要製造商
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模和預測（依藥物類型）
    • 歐洲市場規模與預測（依治療領域）
    • 歐洲市場規模和預測（依分佈）
    • 歐洲市場規模和預測（依最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區癌症支持治療藥物主要製造商
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模和預測（依藥物類型）
    • 亞太地區市場規模和預測（依治療領域）
    • 亞太地區市場規模與預測（依分佈）
    • 亞太地區市場規模和預測（依最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲癌症支持治療藥物主要製造商
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模與預測（依藥物類型）
    • 拉丁美洲市場規模與預測（依治療領域）
    • 拉丁美洲市場規模與預測（依分佈）
    • 拉丁美洲市場規模和預測（依最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲癌症支持治療藥物主要製造商
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模及預測（依藥物類型）
    • 中東和非洲市場規模及預測（依治療領域）
    • 中東和非洲市場規模及預測（依分佈）
    • 中東和非洲市場規模和預測（依最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA其他地區

第12章 主要供應商分析 - 癌症支持治療藥物產業

  • 競爭儀表板
  • 公司簡介
    • Amgen Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Roche Holding AG
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Others

第13章 360 度分析師視角

第14章 附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4105

REPORT HIGHLIGHT

Cancer Supportive Care Drugs Market size was valued at USD 21,410.32 Million in 2023, expanding at a CAGR of 2.31% from 2024 to 2032.

The Cancer Supportive Care Drugs market encompasses medications designed to alleviate the side effects of cancer treatments, enhance patients' quality of life, and support overall health during therapy. Increasing cancer incidence and the rise in treatment options are fueling the demand for supportive care drugs, with the American Cancer Society reporting that approximately 1.9 million new cancer cases are expected in the U.S. in 2024. Moreover, the growing awareness of the importance of palliative care is encouraging healthcare providers to focus on managing treatment-related adverse effects such as nausea, pain, and fatigue. However, challenges such as high costs associated with novel drugs and reimbursement issues can restrain market growth. On the other hand, opportunities lie in the development of personalized supportive care therapies and expanding markets in developing regions, where rising healthcare expenditure and access to innovative treatments are increasing. Additionally, collaborations between pharmaceutical companies and healthcare institutions to enhance drug efficacy and patient outcomes represent a promising avenue for market expansion.

Cancer Supportive Care Drugs Market- Market Dynamics

Rising Cancer Incidence Accelerates Growth in the Cancer Supportive Care Drugs Market

The rising incidence of cancer is significantly driving growth in the Cancer Supportive Care Drugs market, as more patients seek therapies to manage treatment-related side effects. According to the World Health Organization (WHO), cancer is currently the second leading cause of death globally, with nearly 10 million fatalities in 2020. This alarming trend has prompted an increased focus on supportive care options to enhance the quality of life for patients undergoing chemotherapy, radiation, and other treatments. For instance, the American Society of Clinical Oncology (ASCO) emphasizes the importance of managing symptoms such as nausea, pain, and fatigue, which are prevalent among cancer patients. Additionally, organizations like the National Cancer Institute are advocating for research into novel supportive care drugs, further amplifying the demand for effective treatments. As healthcare providers expand their focus on comprehensive cancer care, the market for supportive therapies is expected to flourish, reflecting a critical need to improve patient outcomes in this challenging health landscape.

Cancer Supportive Care Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 2.31% over the forecast period (2024-2032)

Based on Drug Type segmentation, Anti-emetics was predicted to show maximum market share in the year 2023

Based on Therapeutic Area segmentation, Chemotherapy-Induced Nausea, and Vomiting was the leading type in 2023

Based on distribution segmentation, Hospital Pharmacies was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Cancer Supportive Care Drugs Market- Segmentation Analysis:

The Global Cancer Supportive Care Drugs Market is segmented on the basis of Drug Type, Therapeutic Area, Distribution, End-User, and Region.

The market is divided into four categories based on Drug Type: Erythropoiesis-Stimulating Agents, Granulocyte Colony-Stimulating Factors (G-CSFs), Anti-emetics, and Bisphosphonates. Anti-emetics are predicted to show maximum market share due to their essential role in managing chemotherapy-induced nausea and vomiting. Erythropoiesis-stimulating agents follow closely, as they help combat anemia in cancer patients. Granulocyte Colony-Stimulating Factors (G-CSFs) are also significant, supporting neutrophil recovery after chemotherapy. Bisphosphonates, while important for bone health, hold a relatively lower market share compared to the other drug types.

The market is divided into three categories based on Therapeutic Area: Chemotherapy-Induced Nausea and Vomiting, Chemotherapy-Induced Anemia, and Neutropenia. Chemotherapy-induced nausea and Vomiting is the leading therapeutic area, primarily due to the high prevalence of these side effects among cancer patients undergoing treatment. Following this, Chemotherapy-Induced Anemia ranks second, as many patients experience low red blood cell counts due to their therapies. Neutropenia, while also critical, holds a smaller share of the market compared to the other therapeutic areas.

Cancer Supportive Care Drugs Market- Geographical Insights

The geographical landscape of the Cancer Supportive Care Drugs market is characterized by significant growth in North America, particularly in the United States, where a high incidence of cancer and advanced healthcare infrastructure drive demand. According to the American Cancer Society, about 1.9 million new cancer cases were expected in the U.S. in 2024, leading to increased utilization of supportive care drugs. Europe follows closely, with countries like Germany and France investing in innovative treatment options and research initiatives aimed at improving cancer care. Additionally, Asia-Pacific is emerging as a notable region for market expansion, driven by rising healthcare expenditures and increasing awareness of cancer treatment options in countries like China and India. The World Health Organization has emphasized the need for enhanced cancer care in developing regions, further propelling growth in supportive care solutions. As a result, companies are focusing on regional partnerships and tailored marketing strategies to meet the specific needs of these diverse markets.

Cancer Supportive Care Drugs Market- Competitive Landscape:

The competitive landscape of the Cancer Supportive Care Drugs market is marked by the presence of several key players that are actively engaged in developing innovative therapies to meet the growing demand for supportive care. Leading companies such as Amgen, Roche, and Merck are focusing on research and development to enhance their product offerings, particularly in the areas of anti-emetics and granulocyte colony-stimulating factors (G-CSFs). For instance, Amgen's Neulasta (pegfilgrastim) has been a frontrunner in the G-CSF segment, helping to reduce the risk of infection in chemotherapy patients. Collaborations and partnerships are also common, as seen with Bristol-Myers Squibb's alliance with various healthcare institutions to advance research in supportive care. Furthermore, recent acquisitions, such as Pfizer's purchase of Array BioPharma, have strengthened companies' portfolios in cancer therapies, including supportive care drugs. As companies continue to innovate and expand their reach, the competition in this market remains robust, driving advancements that improve patient outcomes in cancer care.

Recent Developments:

In January 2023, Helsinn Healthcare SA and Immedica Pharma AB signed an exclusive long-term agreement to commercialize two cancer-supportive care products, Akynzeo and Aloxi, in key European markets, targeting the prevention of chemotherapy-induced nausea and vomiting.

In August 2024, the FDA approved Augtyro (repotrectinib), a next-generation tyrosine kinase inhibitor, for treating patients with NTRK-positive locally advanced or metastatic solid tumors, enhancing options in cancer supportive care and targeted therapies.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Others

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Erythropoiesis-Stimulating Agents
  • Granulocyte Colony-Stimulating Factors (G-CSFs)
  • Anti-emetics
  • Bisphosphonates

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Chemotherapy-Induced Nausea and Vomiting
  • Chemotherapy-Induced Anemia
  • Neutropenia

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Pediatric Patients
  • Adult Patients
  • Geriatric Patients

GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Cancer Supportive Care Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Cancer Supportive Care Drugs Market Snippet by Drug Type
    • 2.1.2. Cancer Supportive Care Drugs Market Snippet by Therapeutic Area
    • 2.1.3. Cancer Supportive Care Drugs Market Snippet by Distribution
    • 2.1.4. Cancer Supportive Care Drugs Market Snippet by End-User
    • 2.1.5. Cancer Supportive Care Drugs Market Snippet by Country
    • 2.1.6. Cancer Supportive Care Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Cancer Supportive Care Drugs Key Market Trends

  • 3.1. Cancer Supportive Care Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Cancer Supportive Care Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Cancer Supportive Care Drugs Market Opportunities
  • 3.4. Cancer Supportive Care Drugs Market Future Trends

4. Cancer Supportive Care Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Cancer Supportive Care Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Cancer Supportive Care Drugs Market Landscape

  • 6.1. Cancer Supportive Care Drugs Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Cancer Supportive Care Drugs Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 7.1.2. Erythropoiesis-Stimulating Agents
    • 7.1.3. Granulocyte Colony-Stimulating Factors (G-CSFs)
    • 7.1.4. Anti-emetics
    • 7.1.5. Bisphosphonates

8. Cancer Supportive Care Drugs Market - By Therapeutic Area

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapeutic Area, 2023 & 2032 (%)
    • 8.1.2. Chemotherapy-Induced Nausea and Vomiting
    • 8.1.3. Chemotherapy-Induced Anemia
    • 8.1.4. Neutropenia

9. Cancer Supportive Care Drugs Market - By Distribution

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Cancer Supportive Care Drugs Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Pediatric Patients
    • 10.1.3. Adult Patients
    • 10.1.4. Geriatric Patients

11. Cancer Supportive Care Drugs Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Cancer Supportive Care Drugs Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Cancer Supportive Care Drugs Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Cancer Supportive Care Drugs Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Cancer Supportive Care Drugs Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Cancer Supportive Care Drugs Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Cancer Supportive Care Drugs Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Amgen Inc.
    • 12.2.2. AstraZeneca PLC
    • 12.2.3. Bayer AG
    • 12.2.4. Bristol-Myers Squibb Company
    • 12.2.5. Eisai Co., Ltd.
    • 12.2.6. Eli Lilly and Company
    • 12.2.7. F. Hoffmann-La Roche AG
    • 12.2.8. GlaxoSmithKline plc
    • 12.2.9. Johnson & Johnson
    • 12.2.10. Merck & Co., Inc.
    • 12.2.11. Novartis AG
    • 12.2.12. Pfizer Inc.
    • 12.2.13. Roche Holding AG
    • 12.2.14. Sanofi S.A.
    • 12.2.15. Takeda Pharmaceutical Company Limited
    • 12.2.16. Teva Pharmaceutical Industries Ltd.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us